The Chinese protein technology research and development company plans to build a comprehensive protein platform
Yinjia Biosciences (Chinese: 引加生物) announced that it had completed a CNY 100 million Series A financing round, which was led by its existing backer CMB International (Chinese: 招银国际) and followed by InnoPinnacle (Chinese: 苏州信禾国清基金). With the closing of this round, the company has raised three rounds of financing in two years and introduced top investors in healthcare field such as Gaorong Capital (Chinese: 高榕资本), CDH Investments (Chinese: 鼎晖投资), and Shanghai Furong Investment (Chinese: 复容投资).
The funds raised in this round will be mainly used to advance product exports, promote collaboration with global enterprises, continually solidify its unique protein optimization platform, enhance microbial genetic engineering and protein engineering capabilities, and accelerate the construction of synthetic biology technology platform.
Founded in 2020, Yinjia Biosciences is an innovative technology company focusing on applying the use of proteins in biomedicine and other areas. It now has developed more than 50 high-end proteins covering frontier fields such as cell therapy, mRNA vaccine, circRNA, molecular diagnosis, and new antitumor drugs. Yinjia Biosciences has also built laboratories and GMP pilot production platforms in Shanghai, Suzhou and Beijing.
In 2021, Yinjia Biosciences signed a deal with US biotech firm IsoPlexis to jointly advance the use of a multifunctional proteomics data analysis platform that can monitor and analyze the therapeutic effects on tumor patients in real time.
Yinjia's competitors include Acro Biosystems (Chinese: 百普赛斯), Sino Biological (Chinese:义翘神州), and Novo Protein (Chinese: 近岸蛋白).